Table 3.
Univariate analysis for PFS
| Correlative cohort (n = 66) | Anti-EGFR treated (n = 39) | |||
|---|---|---|---|---|
| Median | p | Median | p | |
| Smoking history | 0.246 | 0.238 | ||
| Never smokers | 5.0 | 3.2 | ||
| Former smokers | 5.0 | 5.6 | ||
| Current smokers | 7.0 | 10.0 | ||
| Stage | 0.130 | 0.423 | ||
| IIIB | 7.6 | 11.4 | ||
| IV | 5.0 | 4.8 | ||
| Age | 0.233 | 0.894 | ||
| <70 years | 5.5 | 7.2 | ||
| ≥70 years | 6.5 | 5.0 | ||
| EGFR mutation* | 0.373 | 0.052 | ||
| Exon 19 mutation | 4.4 | 12.7 | ||
| Exon 20 mutation | 8.0 | NA | ||
| Exon 21 mutation | 3.2 | 1.4 | ||
Abbreviations: PFS progression-free survival, NA not applicable. *Analysis is restricted to EGFR mutant patients only.